Seelos Therapeutics, Inc. recently shared an update on initial results from the Phase 2/3 HEALEY ALS Platform trial. The objective of this trial was to assess the effectiveness of SLS-005 in reducing the rate of decline in functional ability and survival rate, compared to a placebo, among individuals with Amyotrophic Lateral Sclerosis.
Although there was no statistically significant improvement in the main outcome measures among the full group of participants, a 13% improvement in survival and functional capacity rates was observed, with an 88% probability of success. This positive effect was noted in a specific pre-identified subgroup of participants, indicating a potential for efficacy in certain situations.
Raj Mehra, the Chairman and CEO of Seelos, stated that they are planning to meet with the FDA to discuss potential next steps for the program, and also planning to continue pursuing potential partnership discussions.
Unfortunately, Seelos Therapeutics saw a 48% decrease in their share price in the pre-market trade on Tuesday.
For additional health-related news, you can visit rttnews.com.
